BCR and B-cell non-Hodgkin lymphoma: Bruton tyrosine kinase inhibitors (BTKi) were selective inhibitors that target B-cell receptor (BCR) signaling, effectively blocking NF-κB activation downstream of BCR signaling and thereby controlling the development of B-cell lymphoma.